Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 18Thoracic 1NET 1Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Prostatic Neoplasms 24Carcinoma, Transitional Cell 6Urinary Bladder Neoplasms 3Carcinoma, Renal Cell 3Small Cell Lung Carcinoma 2Sarcoma 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 2Lung Neoplasms 2Disease 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Brain Neoplasms 2mCRPC (Metastatic Castration-resistant Prostate Cancer) 1Uterine Cervical Neoplasms 1Tuberous Sclerosis 1Thyroid Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Rectal Neoplasms 1Prostate Cancer Metastatic 1Ovarian Neoplasms 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1

Interventions

pembrolizumab 23Nivolumab 20atezolizumab 10Specimen Handling 8Ipilimumab 8Cyclophosphamide 8cabozantinib 6Magnetic Resonance Spectroscopy 6fludarabine 5Sorafenib 5sargramostim 4Trastuzumab 4Sunitinib 4Bevacizumab 4lenvatinib 3enzalutamide 3durvalumab 3avelumab 3X-Rays 3Paclitaxel 3Fluorodeoxyglucose F18 3Docetaxel 3Albumin-Bound Paclitaxel 3ulixertinib 2spartalizumab 2relatlimab 2regorafenib 2palbociclib 2epacadostat 2cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Injections × Genitourinary × Clear all
NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

SAPU NANO (US) LLC

Phase 1 Recruiting
27 enrolled
EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡